InnoBio Fund
VC Fund
Maisons-alfort, France
InnoBio Fund is a VC fund in Maisons-alfort focused on Biotechnology and Therapeutics. InnoBio is a French venture capital fund of €140 million, managed by CDC Enterprises (www.cdcentreprises.fr) and for 37 per cent subscribed by the FSI and leading international pharmaceutical companies in France. The fund makes direct equity and quasi-equity investments in companies that provide innovative technological products and services in thehealthcare market.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries InnoBio Fund invests in
Stages InnoBio Fund invests in
Countries InnoBio Fund invests in
Round sizes
Round size
- Series A
- $16M–$21M
- Series B
- $14M–$21M
- Series C
- $18M–$26M
Investment Focus
Industry
- Biotechnology 10 (71%)
- Therapeutics 6 (43%)
- Pharmaceutical 4 (29%)
- Life Science 3 (21%)
- Medical Device 3 (21%)
Stage
- Series A 2 (14%)
- Series B 2 (14%)
- Series C 2 (14%)
- Funding Round 2 (14%)
- Venture - Series Unknown 2 (14%)
Country
- France 10 (71%)
- United States 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AlgoTherapeutix is the operator of a biotechnology company designed to develop topical treatments for complex pain. | $21.5M / Series B / Mar 14, 2023 | ||
| Diotheris develops bacterial therapies of the human skin and mucosal microbiome intended to protect against pathogenic bacteria. The company's products are based on live bacteria includes NASOFLORE which targets Staphylococcus aureus, enabling the prevention of infections due to major pathogen and protecting patients against biologicalthreats. | Seed / Jul 07, 2020 | ||
| Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need. | $30M / Venture - Series Unknown / Aug 09, 2018 | ||
| Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $17.6M / Mar 20, 2017 | ||
| Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $17.2M / Private Equity / Mar 20, 2017 | ||
| TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technologyplatform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients. | $11.6M / Post-IPO Equity / Feb 24, 2017 | ||
| Sensorion, a Clapiers, France-based biopharmaceutical company specifically dedicated to the development of innovative and targeted therapeutic solutions to treat vestibular deficits. | $4.6M / Venture - Series Unknown / Jan 21, 2015 | ||
| Pixium Vision is developing retinal implant systems for patients who have lost their sight, with the intention of improving their vision and enabling them to lead more independent lives. The Company intends to harness the rapid advances being made in neural processing, micro-electronics and computing to develop retinal implant systems that forblind people could ultimately provide vision approaching that of a normal healthy Pixium's first device, IRIS1 (Intelligent Retinal Implantable System), uses an epi-retinal implant (on the retinal surface) and is currently in clinical trials with the goal of obtaining CE Mark. A second generation system (IRIS2) based on the same format, but offering better visual acuity and featuring several breakthrough technologies, is also under development. In addition, Pixium is developing a sub-retinal implant system (IRIS3), based on further technological breakthroughs, which has the potential to improve vision significantly compared to IRIS1 and IRIS2.Pixium was created in Paris, France in November 2011 as a spin-out of the Vision Institute and Université Pierre et Marie Curie, and based on collaborative work involving several leading academic teams across Europe. Pixium is backed by a syndicate of blue-chip European venture capital firms including Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Seventure and Polytechnos. | $16.5M / Series A / Nov 25, 2013 | ||
| Genticel is a French clinical stage biotechnology company founded by Benedikt Timmerman in 2001 and focused on the development of innovative immunotherapies designed to treat virus infections and virus-induced diseases. Genticel aims to become a leader in immunotherapy in multiple indications, starting with HPV and HPV induced diseases such ascervical cancer. | $20M / Series D / Apr 24, 2013 | ||
| Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time.They believe that targeting cellular energyregulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of those diseases. All three of their clinical stage pipeline programs address significant targets in the energy metabolism pathways. Imeglimin, their lead program, targets mitochondrial dysfunction, mitochondria being the power station of the cell, PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), an important energy sensor, and PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC). | $14.3M / Series B / Dec 18, 2012 | ||
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does InnoBio Fund invest in?
InnoBio Fund invests primarily in Biotechnology, Therapeutics and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is InnoBio Fund's check size?
InnoBio Fund typically joins rounds of $16M–$21M at Series A, $14M–$21M at Series B and $18M–$26M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds InnoBio Fund participates in.
When did InnoBio Fund last invest?
The most recent investment recorded for InnoBio Fund closed in Mar 2023. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
